[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624346":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":43,"collaborators":25,"id":47,"slug":25,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":25,"overallStatus":70,"whyStopped":25,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The University of Texas Health Science Center, Houston","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Transdermal testosterone treatment","ACTIVE_COMPARATOR","Transdermal gel testosterone treatment that will be provided by a clicker",[13],"Other: Transdermal testosterone gel",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Transdermal gel placebo treatment that will be provided by a clicker",[19],"Other: Transdermal placebo gel",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Transdermal testosterone gel","The compounded testosterone gel will be administered using a metered-dose delivery system calibrated to dispense 0.25 mL per actuation, corresponding to an estimated systemic exposure of approximately 300 µg of testosterone per day, within the physiologic range for females.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Transdermal placebo gel","A testosterone-free compounded gel will be delivered via a metered-dose pump calibrated to dispense 0.25 mL per actuation. The placebo gel will use an identical metered-dose delivery system, packaging, and administration instructions.",[15],[31],{"facility":32,"status":25,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":25},"University of Texas","Houston","Texas","77030","United States",{"type":38,"coordinates":39},"Point",[40,41],-95.36327,29.76328,{"lat":41,"lon":40},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Aya Mohr Sasson","Doctor","100624346",false,"NCT07408440","Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause","Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause - A Randomized, Double-blind, Placebo-controlled Trial for Improving Sexual Interest and Desire","TESTA MIND","Inclusion Criteria\n\n* Women 40-65 years; peri- or postmenopausal - with one of the following:\n\n  * Staging by STRAW+10: stage (-2) or above\n  * amenorrhea ≥12 mo\n  * Follicle stimulating hormone in menopausal range\n* FSIAD diagnosis according to the DSM-5: (3\u002F5 of the following symptoms)\n\n  * reduced or no interest in sex\n  * few or no thoughts about sex\n  * decreased sexual arousal or pleasure during sexual activity\n  * reduced or no arousal in response to visual, written, or verbal cues\n  * infrequent or no initiation of sexual activity within a relationship\n  * reduced or no sensations in the genitals\n\nThey must also have:\n\n* symptoms lasting 6 months or more\n* significant distress about their symptoms\n* symptoms that are not more accurately explained by a nonsexual mental health disorder, domestic abuse, medication, substance abuse, or another medical condition\n\n  * In a stable relationship or sexually active opportunity (as defined by participant)\n  * If on systemic estrogen ± progestin or local vaginal estrogen: stable dose ≥8 weeks before randomization and agrees to remain stable\n  * Able to consent and comply with study procedures\n\nExclusion Criteria\n\n* Current or recent (≤8 weeks) androgen therapy, dehydroepiandrosterone (DHEA), or anabolic steroids\n* Total T above premenopausal upper physiologic range at baseline (\\>55 ng\u002FdL)\n* History of hormone-dependent malignancy, untreated endometrial hyperplasia, or active gynecologic malignancy\n* Active severe psychiatric disorder (e.g., untreated major depression), substance use disorder, or relationship violence that precludes attribution of effect\n* Uncontrolled thyroid disease, significant liver disease, increased liver enzymes, or high cardiovascular risk judged unsafe by the primary care provider\n* Pregnancy, attempting conception, or breastfeeding\n* Dermatologic conditions preventing transdermal use; known hypersensitivity to the gel components",true,"FEMALE","40 Years","65 Years",{"count":59,"type":60},150,"ESTIMATED","INTERVENTIONAL",[63],"NA","Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.",[66,67,68,69],"Menopause","Sexual Dysfunction","Libido Disorder","Testosterone Deficiency","NOT_YET_RECRUITING","2026-02-12",{"date":73,"type":74},"2026-02-17","ACTUAL",{"date":76,"type":60},"2026-04-01",{"date":78,"type":60},"2028-03-30",{"name":5,"class":6},1]